VAZALORE’s unique delivery system is intended to predictably release aspirin in the duodenum and decrease exposure to the stomach, which is the most susceptible part of the GI tract to NSAID-induced acute gastric injury.

No other formulation releases aspirin in this way

Preassociating the aspirin in VAZALORE to our pharmaceutical lipid prevents the aspirin from interacting with similar naturally occurring phospholipids in the stomach lining, helping to prevent acute gastric injury.

VAZALORE is available in 81 mg and 325 mg doses

for secondary prevention of vascular events

for secondary prevention of vascular events; pain reliever; fever reducer
With VAZALORE, your patients will receive the benefits of the first major innovation in aspirin therapy in over 50 years.

This innovative, FDA-approved liquid-filled aspirin capsule offers:

- **Bioequivalence to immediate release** aspirin with fast predictable antiplatelet activity
- A unique, lipid-based delivery system designed to protect the stomach
- Targeted release in the duodenum to optimize absorption

**VAZALORE 325 mg** has rigorous clinical studies\(^1,2\)

See **325 mg Clinical Data sheet** included in this packet.

Recommend liquid-filled VAZALORE capsules—**ASPIRIN MADE AMAZING!™**

---

**References:**

©2021 PLx Pharma Inc. All rights reserved. MM00005 060121

To learn more about how VAZALORE can help your patients, visit VazaloreHCP.com